Companies › Corregene Biotechnology
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KRAS-specific Autologous TCR-T cell injection (CRTKVA11-N04) KRAS G12V-specific T-cell receptor engineered T-cell therapy | KRAS | Phase 1 | Colorectal | Nov 2028 |
| CRTKVA11-03 TCR-T Cell Injection KRAS G12V-specific autologous TCR-T cells | – | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06767046 | KRAS-specific Autologous TCR-T cell injection (CRTKVA11-N04) | Phase 1 | Colorectal | Oncology | Nov 2028 |
| NCT07826585 | CRTKVA11-03 TCR-T Cell Injection | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.